Introduction {#section1-1073274820922540}
============

Cervical cancer is the fourth most common cancer in women of about 570 000 of new cases in 2018.^[@bibr1-1073274820922540]^ Most of the cases are distributed in developing countries.^[@bibr1-1073274820922540]^ Ineffective screening program and low level of coverage of the target population are the main reasons of a high burden of disease.^[@bibr2-1073274820922540][@bibr3-1073274820922540]--[@bibr4-1073274820922540]^ In Thailand, the current cervical cancer screening program has been found to be ineffective.^[@bibr5-1073274820922540]^ The main strategy used is cytology-based screening. Human papilloma virus (HPV) testing has been used in conjunction with cytology and used for triage of cervical cytology showing atypical squamous cells of undetermined significance (ASCUS). To improve the efficacy and increase the coverage of screening, several new strategies have been studied.^[@bibr6-1073274820922540][@bibr7-1073274820922540][@bibr8-1073274820922540][@bibr9-1073274820922540][@bibr10-1073274820922540]--[@bibr11-1073274820922540]^ Our previous study compared the cost and benefit of 4 different cervical cancer screening strategies involving primary HPV 16/18 genotyping, high-risk HPV testing, liquid-based cytology, and conventional cytology.^[@bibr12-1073274820922540]^ Model predictions indicated that the most cost-effectiveness strategy is primary high-risk HPV testing by reducing cost and also increase the detection of cervical intraepithelial neoplasia 2 and 3. However, the primary HPV testing still has some problem because of its high sensitivity and low specificity. This may cause overtreatment. The concept of dual stain has been introduced to decreased overtreatment case. One systematic literature review showed that across all age groups in a screening population, dual staining was significantly more sensitive than and equally specific as cytology.^[@bibr13-1073274820922540]^ Specificity gains resulted in fewer false positives and an increase in the number of correct referrals to colposcopy. Dual staining with p16/Ki-67 cytology is an attractive biomarker approach for triage in cervical cancer screening.^[@bibr13-1073274820922540]^

Our recent study assessed the clinical and cost-effectiveness of HPV primary screening triage with p16/Ki-67 dual stain cytology compared to cytology. The preliminary result suggests that screening by use of HPV genotyping test and dual stain cytology as the triage test for other high-risk HPV positive women as a primary screening test in Thai population 30 to 65 years old is expected to be more cost-effective than cytology.^[@bibr14-1073274820922540]^ Based on the available results of cost-effectiveness analysis study in Thailand, the objective of this study is to evaluate the cost and effectiveness of HPV-based primary screening strategies with different triage including Papanicolaou (Pap) cytology and p16/Ki67 dual stain cytology in Thai population 30 to 65 years old in order to implement the most appropriate strategy to our country.

Materials and Methods {#section2-1073274820922540}
=====================

Epidemiologic Modeling {#section3-1073274820922540}
----------------------

We developed a computer simulation model (A Microsoft Excel--based spreadsheet) to calculate the number of accumulated cases of cervical intraepithelial neoplasia, invasive cervical cancer, and budget impact of each screening program. The model of natural history was constructed ([Figure 1](#fig1-1073274820922540){ref-type="fig"}). Individual women enter the model at age of 30 years. They face the yearly probabilities of transitioning between HPV-related health stages, including well, high-risk HPV infection, cervical intraepithelial neoplasia, invasive cervical cancer, and death. The simulation model continued until women had died or diagnosed with cervical intraepithelial neoplasia 2, cervical intraepithelial neoplasia 3, and cancer.

![Model natural history of cervical cancer.](10.1177_1073274820922540-fig1){#fig1-1073274820922540}

Screening and Management Algorithms {#section4-1073274820922540}
-----------------------------------

The study population for our simulation was a closed cohort representing the Thai population 30 to 65 years of age which is an approximately 26.6% of the total population. The screening coverage was 50% of the target population.^[@bibr15-1073274820922540],[@bibr16-1073274820922540]^ Based on the total number of Thai population (in 2015) and excluding the women with HIV infection, history of hysterectomy and pregnant, 7 953 963 were eligible for screening.^[@bibr17-1073274820922540]^

We examined 3 different algorithms of primary HPV assay based on the evidence of cost-effectiveness data from our previous studies.^[@bibr12-1073274820922540],[@bibr14-1073274820922540]^ According to the clinical guideline of the National cancer institute of Thailand, all strategies were considered a 5-year interval. The decision tree models of screening and management algorithms are displayed in [Figure 2](#fig2-1073274820922540){ref-type="fig"}.

![Screening model. A, Pooled HPV test with reflex LBC triage. B, HPV genotyping test with reflex dual stain. HPV indicates human papilloma virus.](10.1177_1073274820922540-fig2){#fig2-1073274820922540}

1.  High-risk HPV testing with reflex liquid-based cytology (LBC) triage: Pooled high-risk HPV testing is a primary tool, followed by LBC for women with the high-risk HPV positive result. A cytology of ASCUS or worse leads to immediate colposcopy. A repeat HPV testing at 12 months will be performed for HR-HPV-positive women with normal cytology. If the result of high-risk HPV is negative, the women will return to routine screening in 5 years ([Figure 2A](#fig2-1073274820922540){ref-type="fig"}).

2.  Human papilloma virus with 16/18 genotyping and reflex dual stain: Screening with HPV genotyping then refers to colposcopy if the result is positive for HPV 16 or 18. The dual staining is performed in cases of other 12 high-risk HPV positive and those with positive result undergo colposcopy. For those who negative dual staining, HPV testing will be done at 12 months interval. Women with a negative result of HPV genotyping return to screening in 5 years ([Figure 2B](#fig2-1073274820922540){ref-type="fig"}).

3.  High-risk HPV testing and reflex dual stain: using high-risk HPV testing alone every 5 years followed by dual stain if the result is positive for high-risk HPV. The women with positive results of both high-risk HPV testing and dual stain will refer to perform colposcopy. Repeat the HPV test in 12 months for a woman with HR-HPV-positive and -negative dual staining ([Figure 2C](#fig2-1073274820922540){ref-type="fig"}).

Model Assumptions {#section5-1073274820922540}
-----------------

Colposcopy was considered to be a gold standard for diagnosis of a precancerous lesion with 100% sensitivity and specificity. Disease progression and regression were assumed to be constant over time and not to be age-specific. The model assumes that the loss to follow-up rate in all strategies were the same and thus will not affect the comparative result. Based on expert's opinion, we assumed that all cervical intraepithelial neoplasia 3 cases and 50% of cervical intraepithelial neoplasia 2 received treatment. Women with cervical intraepithelial neoplasia 1 or posttreatment cervical intraepithelial neoplasia 2+ returned to follow-up every 6 months. Cervical intraepithelial neoplasia 1 patients with 2 times of negative results and cervical intraepithelial neoplasia 2+ patients with 4 times of negative results would return to routine screening.^[@bibr18-1073274820922540]^

Four percent of cervical intraepithelial neoplasia 2 to 3 and 20% of invasive cervical cancer were assumed to be recurred after treatment^[@bibr19-1073274820922540]^; they would stay in the current status or progress to more severe states in the model. We considered both deaths from cervical cancer and all-cause mortality.

The Model Outcome, Cost Data, and Cost-Effectiveness {#section6-1073274820922540}
----------------------------------------------------

Based on case values used in the model were mainly based on the data from the published literature referenced in [Tables 1](#table1-1073274820922540){ref-type="table"} and [2](#table2-1073274820922540){ref-type="table"}. The outcomes for the model included: screening performances, a total number of cancer and precancerous cases detected, and life expectancy adjusted for quality of life. Age-adjusted annual probabilities of death without cervical cancer were derived from the general population estimates reported in Estimated Generation Life Tables for Thailand of 5-Year Birth Cohorts: 1900-2000.^[@bibr20-1073274820922540]^ We conducted the analysis from provider's perspective. The cost component used for the cost evaluation are depicted in [Table 2](#table2-1073274820922540){ref-type="table"}. Screening costs and treatment cost were derived from our previous studies which based on the cost of the Center of Health Assurance at King Chulalonglongkorn Memorial Hospital and Roche Diagnostic, Thailand.^[@bibr12-1073274820922540],[@bibr14-1073274820922540],[@bibr21-1073274820922540]^ Only direct medical cost was included. Indirect costs such as loss of productivity and transportation costs were assumed to have the same among patients. The cancer treatment cost is the median cost across all stages. All clinical and cost inputs were discounted at an annual rate of 3.5%.^[@bibr22-1073274820922540]^ The results of cost-effectiveness analysis were presented by incremental cost-effectiveness ratios (ICERs) per quality-adjusted life years (QALY) which is the additional cost divided by additional QALY, compared to the next most costly strategy. We used Thailand's gross domestic product (GDP) per capita to evaluate the most cost-effectiveness strategy which is suggested by the World Health Organization (WHO). An ICER of less than 3 times the per capita GDP would be considered cost effective.^[@bibr23-1073274820922540]^

###### 

Clinical Parameters.

![](10.1177_1073274820922540-table1)

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  The Performance of Screening Test^[@bibr26-1073274820922540],[@bibr27-1073274820922540]^                                                                                                                                                                                                               Input Value
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ -------------
  Cytology (threshold = ASCUS)                                                                                                                                                                                                                                                                           

   Sensitivity of cytology for cervical intraepithelial neoplasia 2                                                                                                                                                                                                                                      53.20%

   Sensitivity of cytology for cervical intraepithelial neoplasia 3                                                                                                                                                                                                                                      57.70%

   Sensitivity of cytology for invasive cervical carcinoma                                                                                                                                                                                                                                               57.70%

   Specificity of cytology                                                                                                                                                                                                                                                                               73.40%

  HPV testing                                                                                                                                                                                                                                                                                            

   Sensitivity of pooled high-risk HPV testing for cervical intraepithelial neoplasia 2                                                                                                                                                                                                                  86.40%

   Sensitivity of pooled high-risk HPV testing for cervical intraepithelial neoplasia 3                                                                                                                                                                                                                  89.90%

   Sensitivity of pooled high-risk HPV testing for invasive cervical carcinoma                                                                                                                                                                                                                           89.90%

   Specificity of pooled high-risk HPV testing                                                                                                                                                                                                                                                           62.70%

   Sensitivity of genotyping 16/18 for cervical intraepithelial neoplasia 2                                                                                                                                                                                                                              43.60%

   Sensitivity of genotyping 16/18 for cervical intraepithelial neoplasia 3                                                                                                                                                                                                                              53.40%

   Sensitivity of genotyping 16/18 for invasive cervical cancer                                                                                                                                                                                                                                          59.20%

   Specificity of genotyping 16/18                                                                                                                                                                                                                                                                       91.90%

  Dual staining                                                                                                                                                                                                                                                                                          

   Pooled HPV triage                                                                                                                                                                                                                                                                                     

   Sensitivity for cervical intraepithelial neoplasia 2                                                                                                                                                                                                                                                  86.80%

   Sensitivity for cervical intraepithelial neoplasia 3                                                                                                                                                                                                                                                  89.80%

   Specificity for cervical intraepithelial neoplasia 2+                                                                                                                                                                                                                                                 71.40%

   Sensitivity for invasive cervical cancer                                                                                                                                                                                                                                                              93.80%

  Epidemiology data^[@bibr26-1073274820922540][@bibr27-1073274820922540][@bibr28-1073274820922540][@bibr29-1073274820922540][@bibr30-1073274820922540][@bibr31-1073274820922540][@bibr32-1073274820922540]--[@bibr33-1073274820922540]^                                                                  Input\
                                                                                                                                                                                                                                                                                                         value

   Prevalence of high-risk HPV                                                                                                                                                                                                                                                                           5.6%

   Prevalence of HPV16 and 18                                                                                                                                                                                                                                                                            1.7%

   Prevalence of cervical intraepithelial neoplasia 1                                                                                                                                                                                                                                                    0.6%

   Prevalence of cervical intraepithelial neoplasia 2                                                                                                                                                                                                                                                    0.3%

   Prevalence of cervical intraepithelial neoplasia 3                                                                                                                                                                                                                                                    0.8%

   Prevalence of invasive cervical cancer                                                                                                                                                                                                                                                                0.075%

   General population annual death rate                                                                                                                                                                                                                                                                  0.800%

   % of high grade squamous intraepithelial lesion (HSIL) + population that is HPV+                                                                                                                                                                                                                      88.4%

   % of low grade squamous intraepithelial lesion (LSIL) population that is HPV+                                                                                                                                                                                                                         61.5%

   % of atypical squamous cells of undetermined significant (ASCUS) population that is HPV+                                                                                                                                                                                                              21.4%

   % cervical intraepithelial neoplasia 1 that are high-risk HPV 16/18                                                                                                                                                                                                                                   13.6%

   % cervical intraepithelial neoplasia 2 that are high-risk HPV 16/18                                                                                                                                                                                                                                   23.1%

   % cervical intraepithelial neoplasia 3 that are high-risk HPV 16/18                                                                                                                                                                                                                                   50.3%

   % of invasive cervical carcinoma that are high-risk HPV 16/18                                                                                                                                                                                                                                         75.0%

  Natural history parameters ^[@bibr31-1073274820922540],[@bibr34-1073274820922540][@bibr35-1073274820922540][@bibr36-1073274820922540][@bibr37-1073274820922540][@bibr38-1073274820922540][@bibr39-1073274820922540][@bibr40-1073274820922540][@bibr41-1073274820922540]--[@bibr42-1073274820922540]^   Input\
                                                                                                                                                                                                                                                                                                         value

   Progression                                                                                                                                                                                                                                                                                           

    Well to high-risk HPV infection                                                                                                                                                                                                                                                                      3.20%

    Transformation from high-risk HPV (12 types) to:                                                                                                                                                                                                                                                     

     cervical intraepithelial neoplasia 1                                                                                                                                                                                                                                                                9.10%

     cervical intraepithelial neoplasia 2 (3year FU Luyten)                                                                                                                                                                                                                                              0.10%

     cervical intraepithelial neoplasia 3                                                                                                                                                                                                                                                                0.10%

    Transformation from high-risk HPV 16/18 to:                                                                                                                                                                                                                                                          

     cervical intraepithelial neoplasia 1                                                                                                                                                                                                                                                                7.30%

     cervical intraepithelial neoplasia 2                                                                                                                                                                                                                                                                2.20%

     cervical intraepithelial neoplasia 3                                                                                                                                                                                                                                                                2.00%

    Progression from cervical intraepithelial neoplasia 1                                                                                                                                                                                                                                                

     to cervical intraepithelial neoplasia 2                                                                                                                                                                                                                                                             3.10%

     to cervical intraepithelial neoplasia 3                                                                                                                                                                                                                                                             0.90%

    Progression from cervical intraepithelial neoplasia 2                                                                                                                                                                                                                                                

     to cervical intraepithelial neoplasia 3 (2year FU, Luyten)                                                                                                                                                                                                                                          4.20%

     to invasive Cervical Cancer                                                                                                                                                                                                                                                                         0.00%

     to cervical intraepithelial neoplasia 3 to invasive Cervical Cancer                                                                                                                                                                                                                                 4.50%

    Annual mortality rate for cervical cancer                                                                                                                                                                                                                                                            8.30%

   Regression                                                                                                                                                                                                                                                                                            

    Regression from high-risk HPV (12 types) to:                                                                                                                                                                                                                                                         

     with NORMAL smear to well                                                                                                                                                                                                                                                                           58.60%

     with BORDERLINE/MILD smear to well                                                                                                                                                                                                                                                                  45.60%

    Regression from high-risk HPV 16/18 to:                                                                                                                                                                                                                                                              

     with NORMAL smear to well                                                                                                                                                                                                                                                                           43.80%

     with BORDERLINE/MILD smear to well                                                                                                                                                                                                                                                                  21.80%

    Regression from cervical intraepithelial neoplasia 1                                                                                                                                                                                                                                                 

     to well                                                                                                                                                                                                                                                                                             21.20%

     to high-risk HPV                                                                                                                                                                                                                                                                                    2.40%

    Regression from cervical intraepithelial neoplasia 2                                                                                                                                                                                                                                                 

     to well                                                                                                                                                                                                                                                                                             9.40%

     to cervical intraepithelial neoplasia 1                                                                                                                                                                                                                                                             9.40%

    Regression from cervical intraepithelial neoplasia 3                                                                                                                                                                                                                                                 

     to well                                                                                                                                                                                                                                                                                             3.80%

     to cervical intraepithelial neoplasia 1                                                                                                                                                                                                                                                             1.60%
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: HPV, human papilloma virus.

###### 

Cost Parameters.^a^

![](10.1177_1073274820922540-table2)

  Cost                                                    Input Value (USD)
  ------------------------------------------------------- -------------------
  Screening costs^[@bibr21-1073274820922540]^             
   Office visit (routine/repeat screening)                2.00
   Cytology test (lab fee)                                5.30
   Cytology test (professional fee)                       3.00
   HPV DNA test                                           17.00
   P16/Ki67 dual staining                                 35.00
  Diagnostic costs^[@bibr21-1073274820922540]^            
   Office visit (diagnostic follow-up)                    12.86
   Colposcopy plus biopsy                                 21.42
  Treatment costs^[@bibr21-1073274820922540]^             
   Treatment for cervical intraepithelial neoplasia 2/3   1292.00
   Treatment for invasive cervical cancer                 7403.00
   End of life cancer treatment cost                      10019.00
  Discounting rate                                        
   Discount rate for cost                                 0.035
   Discount rate for health outcomes                      0.035

Abbreviation: HPV, human papilloma virus.

^a^ The currency used was USD (US Dollar exchange rate on March 1, 2019, US\$1 = 32 THB).

Sensitivity Analysis {#section7-1073274820922540}
--------------------

A one-way sensitivity of cost parameter of the screening tools in each strategy was performed in order to evaluate the uncertainty in which parameters might affect the ratio. The costs were varied 10% below and 3 times above the base case estimation.

Results {#section8-1073274820922540}
=======

Base Case Analysis {#section9-1073274820922540}
------------------

The screening performances are shown in [Table 3](#table3-1073274820922540){ref-type="table"} which are presented in term of the number and percentage of cervical cancer and precancer cases detected. Human papilloma virus genotyping as the primary screen with triage of non16/18 HPV-positives using p16/Ki67 dual stain cytology (strategy 2) was the most effective strategy. Almost 90% of cervical cancer cases could be detected by this strategy. Pooled high-risk HPV primary with reflex dual stain cytology was nearly as effective (strategy 3). Relative to Pooled high-risk HPV testing with reflex LBC (strategy 1), the use of dual staining p16/Ki67 test for triage of HPV-positive women did not only increase but also improves the QALY. Human papilloma virus genotyping test with reflex dual stain strategy (strategy 2) decreased the total lifetime cost by US\$964 822 and US\$4 015 670 when compared to pooled high-risk HPV test alone and pooled high-risk HPV test with reflex dual stain test, respectively. The cost-effectiveness analysis was also presented in the ICER plane (Supplemental Material 1). The result showed the strategies of pooled high-risk HPV test with reflex LBC (strategy 1) were dominated by HPV genotyping with dual stain (strategy 2). Regarding the 2 strategies using reflex dual stain: Primary test with pooled high-risk HPV was not cost effective when compared with primary test with HPV genotyping due to the high ICER value (US\$416 912/QALY gain) which revealed more than 3 times of Thailand GPD (Thailand GDP per capita 2017: US\$6125.75.^[@bibr24-1073274820922540]^ Comparing strategies 3 and 1, pooled high-risk HPV test with reflex LBC was less costly than with dual stain cytology, whereas pooled high-risk HPV test with reflex dual stain provided a more effective strategy at an ICER of US\$353.40 per QALY gained. The cost-effectiveness frontier between total cost and QALY gained of each strategy is presented in Supplemental Material 2. Strategy 1 or pooled high-risk HPV testing with reflex LBC was not on the frontier and fell to the right side of the solid line, meaning that it was not an efficient use of resources. Comparing strategy 3 and strategy 2, pooled high-risk HPV test with reflex dual stain cytology was clearly dominated by HPV genotyping with reflex dual staining (same benefit but higher cost).

###### 

Base Case Results of Outcome, Cost, and ICER per QALY Gained.

![](10.1177_1073274820922540-table3)

                                                   HPV Genotyping Test With Reflex Dual Stain (Strategy 2)   Pooled HPV Test With Reflex LBC (Strategy 1)   Pooled HPV Test With Reflex Dual Stain (Strategy 3)
  ------------------------------------------------ --------------------------------------------------------- ---------------------------------------------- -----------------------------------------------------
  Screening performance (%)                                                                                                                                 
   Cervical cancer detected                        88.9                                                      73.5                                           87.4
   Cervical intraepithelial neoplasia 3 detected   85.2                                                      73.3                                           85.9
   Cervical intraepithelial neoplasia 2 detected   79.2                                                      67.7                                           81.2
  Total number of cases detected                                                                                                                            
   Cervical cancer detected                        31 607                                                    35 577                                         31 765
   Cervical intraepithelial neoplasia 3 detected   257 188                                                   240 952                                        260 658
   Cervical intraepithelial neoplasia 2 detected   230 669                                                   200 524                                        239 577
  Average QALY                                     24.029947                                                 23.98                                          24.029999
  Total cost (USD)                                 1 326 269 261                                             1 360 038 064                                  1 500 586 513
  Total cost per person (USD)                      167                                                       171                                            189
  Incremental cost per person (USD)                --                                                        4                                              18
  Incremental effectiveness                        --                                                        −0.049947433159300                             0.0499999999995993
  ICER^a^ (USD/ QALY gained)                       --                                                        −85^b^                                         353.405

Abbreviations: HPV, human papilloma virus; ICER; Incremental cost and effectiveness; LBC, liquid-based cytology; QALY, Quality adjust life year.

^a^ The difference in cost divided by the difference in detected case for each strategy compared with the next best strategy.

^b^ Strategies shown cost more but were less effective than the next most expensive strategy and were therefore dominated.

Sensitivity Analysis {#section10-1073274820922540}
--------------------

The model sensitivity was measured by the absolute percentage change in ICER induced by decreasing 10% below and increasing 3 times perturbation in the parameters (Supplemental Materials 3 and 4). More significant changes were found in scenarios related to changes in the costs of dual stain cytology test and cancer treatment. However, HPV genotyping test with reflex dual stain still was the optimal strategy.

Discussion {#section11-1073274820922540}
==========

Evidence suggests that primary HPV testing can be more effective than cytology and additional triage tests are needed to identify women with progressing disease. The triage strategies include HPV genotyping for HPV 16/18, cytology, p16/Ki67 dual stain cytology, host methylation, and viral methylation testing.^[@bibr25-1073274820922540]^ It is still not clear what the best strategy for triage of screen-positive women is. To find an optimal integrated screening and triage strategy for Thai women, we conducted the cost-effectiveness analysis study and reported the primary high-risk HPV testing with reflex LBC was preferred over primary liquid base cytology as it was more effective and less costly.^[@bibr12-1073274820922540]^ We then applied the HPV model by using p16/Ki67 dual stain cytology as triage for high-risk HPV-positive women (non16/18 HPV positive) and compared with primary cytology. The result showed the good performance of p16/ki67 dual stain cytology and reported that HPV genotyping with reflex dual stain was more costly but more effective than cytology method with an ICER was 1395 per QALY.^[@bibr14-1073274820922540]^

From this cost-effectiveness analysis, it can be concluded that HPV primary plus genotyping with reflex dual stain cytology every 5 years for Thai women at age of 30 to 65 was the most effective strategy according to a cost-effectiveness threshold based on per capita GDP. Comparing to pooled high-risk HPV test with reflex LBC, the higher cost of diagnostics test was compensated by higher screening performance and lower cost of treatment. Wright et al assessed the performance of dual stain cytology compared with cytology for triaging HPV-positive women undergoing primary HPV screening. The result showed sensitivity, positive predictive value, and negative predictive value were higher for dual staining than cytology, in a similar way to our result.^[@bibr16-1073274820922540]^ Uijterwaal et al reported dual stain cytology had a sensitivity of more than 70% for cervical intraepithelial neoplasia 2/3 and the cumulative 5-year cervical intraepithelial neoplasia 3 risk was significantly reduced in dual stain negative women.^[@bibr11-1073274820922540]^ It is therefore suitable for triaging to colposcopy. From our study, the use of dual staining in either strategy 2 or 3 increased the number of precancerous cases detected which resulted in decreased cancer cases detected. One prospective study in HPV-positive women revealed that the dual stain cytology had similar sensitivity and higher specificity compared with cytology for detection cervical intraepithelial neoplasia 2/3 cases.^[@bibr9-1073274820922540]^ Until now, there are no data that how long dual stain negative women remain at low risk of precancerous. Women with positive HPV and negative dual stain in our model were retested with HPV testing, while women with positive HPV and negative cytology were returned to routine screening. If the women with positive HPV and negative dual staining were returned to routine safety, the total cost of strategies 2 and 3 would decrease and these 2 strategies would be more cost-effective than cytology triaging.

Comparing between primary pooled high-risk HPV primary testing with dual stain cytology (strategy 3) and primary HPV genotyping with dual stain cytology (strategy 2), the clinical outcomes were comparable but strategy 3 was more costly. Both strategies included dual stain cytology which was one of the most expensive diagnostic tests. A larger number of women in strategy 3 were sent for dual stain cytology while HPV 16/18-positive women in strategy 2 were referred directly to colposcopy. This may cause strategy 3 to be the most expensive strategy. One-way sensitivity analysis also confirmed this reason, if the cost of dual staining increased 3 times, the ICER between strategy 3 versus 1 and 3 versus 2 would increase to 114% and 23.97%, respectively. The cost of cancer treatment was another factor that affected the ICER result, the ICER between strategies 3 versus 2 increased almost twice when cancer treatment cost increased 3 times. In the first screening round, the total cost in strategy 2 may be slightly higher than strategy 3 because more cancer cases were detected and treated. However, the number of women would be reduced in the next screening round and the detection of cancer cases would be lower. This results in decreasing the cost of cancer treatment in long term for strategy 2.

To the best of our knowledge, this is the first economic study to evaluate an optimal triage strategy for HPV-positive women in Thailand. Our analysis included both direct costs of screening and treatment, and we presented the screening performance, a number of cases detected, QALY and screening budget of each strategy. However, there were some limitations of our study. First, several clinical input parameters of the model were derived from Western literature and the percentage of cervical intraepithelial neoplasia cases received treatment were based on the expert's opinion. Second, since there were no Thai data available, we did not use the age-specific progression rates for HPV acquisition, clearance, progression from HPV infection to cervical intraepithelial neoplasia 2/3 and cancer. Third, our analysis calculated the cost from Thai Government Hospital which limited applicability to health-care settings in other countries. We tried to minimize this limitation by using the asymmetrical distribution of the cost to right-hand tail in sensitivity analysis because the costs we used were lower compared to the average cost of overall hospital in Thailand. To clarify the most suitable strategy for implementation of cervical cancer screening in Thailand, further studies are necessary. The clinical parameters should be based on the updated data from several regions of Thailand. Indirect cost such as cost of day loss should be incorporated to estimate the total cost of illness based on social perspective. Finally, increasing HPV vaccination coverage will lead to lower prevalence of HPV16/18 infection or higher prevalence of other high-risk HPV infection, which will further reduce the efficacy of strategy 2.

In summary, the findings from this study emphasizes the importance of dual stain cytology as a triage test for high risk HPV-positive women. The strategy of primary HPV genotyping test with dual stain cytology every 5 years interval was the most cost-effective screening method and should be considered for implementation in practice and for future guidelines.

Supplemental Material {#section12-1073274820922540}
=====================

###### Supplementary - Cost-Effectiveness of Primary HPV Screening Strategies and Triage With Cytology or Dual Stain for Cervical Cancer

###### 

Click here for additional data file.
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